X

Trial Profile

A prospective double-blind randomized phase I clinical trial of BRII-778 for HIV-infections in healthy adults subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BRII 778 (Primary)
Indications HIV infections
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

19 Oct 2022 Results published in the Brii Biosciences Media Release.
23 Aug 2022 According to Brii Biosciences media release, this trial will be presented at the IDWeek Conference in October 2022.
22 Mar 2022 According to Brii Biosciences media release, Phase 1 SAD/MAD data will be published at a future scientific conference in the second half of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com